Dr. Michael J. Wagner
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 106
Licensed in Washington since 2017, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Harvard Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 1016422 · WA license MD60759395 (first issued 2017; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Beth Israel Deaconess Medical Center Boston, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 106
- Services billed
- 254
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 104 | 68 |
| Established patient office or other outpatient visit, 40-54 minutes | 68 | 43 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $4,135 in total to this clinician.
| Springworks Therapeutics, Inc. | $3,555 |
|---|---|
| Deciphera Pharmaceuticals Inc. | $580 |
| Consulting Fee | $3,555 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $580 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Springworks Therapeutics, Inc. Apr 24, 2025 | Consulting Fee OGSIVEO · DESMOID TUMORS | $1,185 |
| Springworks Therapeutics, Inc. Mar 26, 2025 | Consulting Fee GOMEKLI · NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS | $790 |
| Springworks Therapeutics, Inc. Mar 26, 2025 | Consulting Fee OGSIVEO · DESMOID TUMORS | $790 |
| Springworks Therapeutics, Inc. Sep 11, 2025 | Consulting Fee OGSIVEO · DESMOID TUMORS | $790 |
| Deciphera Pharmaceuticals Inc. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $580 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $180,118 in research payments for these studies, mostly to the institutions running them.
- First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo Inc. · Recruiting · NCT06644755 - Spearhead-1
Adaptimmune LLC - A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.